Telomerase Upregulation Induces Progression of Mouse BrafV600E-Driven Thyroid Cancers and Triggers Nontelomeric Effects.

Unlabelled: Mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the paradigm of a cross-cancer alteration in a noncoding region. TERT promoter mutations (TPM) are biomarkers of poor prognosis in cancer, including thyroid tumors. TPMs enhance TERT transcription, which is otherwise silenced in adult tissues, thus reactivating a bona fide oncoprotein.

Telomerase reactivation induces progression of mouse Braf -driven thyroid cancers without telomere lengthening.

Mutations in the promoter of the telomerase reverse transcriptase ( ) gene are the paradigm of a cross-cancer alteration in a non-coding region. promoter mutations (TPMs) are biomarkers of poor prognosis in several tumors, including thyroid cancers. TPMs enhance transcription, which is otherwise silenced in adult tissues, thus reactivating a oncoprotein.

Multiple ETS Factors Participate in the Transcriptional Control of Mutant Promoter in Thyroid Cancers.

Hotspot mutations in the (telomerase reverse transcriptase) gene are key determinants of thyroid cancer progression. promoter mutations (TPM) create de novo consensus binding sites for the ETS ("E26 transformation specific") family of transcription factors. In this study, we systematically knocked down each of the 20 ETS factors expressed in thyroid tumors and screened their effects on TERT expression in seven thyroid cancer cell lines with defined TPM status.